Analyst Ratings for Entrada Therapeutics (TRDA)
TRDA Rating Summary
TRDA Price Target Summary
- Highest: $23.00 (Oppenheimer)
- Lowest: $17.00 (Guggenheim)
- Average: $20.00
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$20.00 (+321.1%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 78%
Avg. $ Target:
$20.00 (+321.1%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 78%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/8/2026 | H.C. Wainwright » Updated 10/19/2026 |
Boobalan Pachaiyappan | Downgrade | Neutral (Buy) |
N/A (N/A) |
6.85 (4.75) |
-30.66% | Details |
| 4/1/2026 | Cantor Fitzgerald | Yanni Souroutzidis | New Coverage | Overweight (N/A) |
N/A (N/A) |
12.62 (4.75) |
-62.36% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
